Clinical trials: Advanced Solid Malignancy
Advanced Solid Tumors, HER2-positive Breast Cancer
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors.
- Trial name
- NCT04487236
- Testing
- ZN-A-1041 50mg BID, ZN-A-1041 100mg BID, ZN-A-1041 200mg BID
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Suzhou Zanrong Pharma Limited
Solid Tumors
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
This is an entry-into-human study and will assess the effects of eciskafusp alfa (RO7284755) as a single agent and in combination with atezolizumab in adult participants with solid tumors considered responsive to checkpoint…
- Trial name
- NCT04303858
- Testing
- Eciskafusp Alfa, Atezolizumab
- Where
- 12 sites in Belgium, Denmark and 3 more
- Volunteers
- 189 people
- Sponsor
- Hoffmann-La Roche
Neoplasm Metastases
A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
The purpose of this study is to evaluate the potential effects of ketoconazole on blood levels of trabectedin after administration to patients with advanced malignancies.
- Trial name
- NCT01267084
- Testing
- Trabectedin, Ketoconazole, Dexamethasone or equivalent steroid
- Where
- 2 sites in Belgium
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumors, Aggressive B-cell Lymphomas
A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736 (durvalumab), or rituximab in participants with either…
- Trial name
- MEDI6469 (NCT02205333)
- Testing
- MEDI6469 Monotherapy, MEDI6469 Plus Tremelimumab, MEDI6469 Plus Durvalumab
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- MedImmune LLC
Neoplasms
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
This study will evaluate the maximum tolerated dose and dose-limiting toxicities of vemurafenib and/or cobimetinib when used with onartuzumab in cancer patients.
- Trial name
- NCT01974258
- Testing
- Cobimetinib, Onartuzumab, Vemurafenib
- Where
- 6 sites in United States
- Sponsor
- Hoffmann-La Roche
Solid Tumors
A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body
This study is open to adults with advanced cancer (solid tumours). People for whom previous treatment was not successful or no treatment exists can take part. This study tests a medicine called BI 907828.
- Trial name
- NCT05613036
- Testing
- [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1), [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2), BI 907828
- Where
- Hungary
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Advanced Solid Tumors
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, drug levels, immunogenicity and preliminary efficacy of BMS-986213 (nivolumab-relatlimab fixed-dose combination) in Chinese participants with advanced solid tumors.
- Trial name
- RELATIVITY 059 (NCT05134948)
- Testing
- BMS-986213
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Ovarian Cancer
FPA150 in Patients With Advanced Solid Tumors
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
- Trial name
- FPA150-001 (NCT03514121)
- Testing
- FPA150, Pembrolizumab
- Where
- 18 sites in United States, South Korea
- Volunteers
- 95 people
- Sponsor
- Five Prime Therapeutics, Inc.
Advanced Malignant Solid Tumors
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150…
- Trial name
- NCT07566247
- Testing
- AK150
- Where
- 3 sites in China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Akeso
Solid Tumor
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety/tolerability, pharmacokinetics, and efficacy of GFS101A in combination with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT05165849
- Testing
- GFS101A, Toripalimab
- Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
Patients With Advanced Solid Tumors
A Study of ICP-033 in Patients With Advanced Solid Tumors
A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-033 Tablets in Patients with Advanced Solid Tumors.
- Trial name
- NCT05367232
- Testing
- ICP-033 tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Advanced Solid Tumors
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study.
- Trial name
- NCT06959706
- Testing
- TGW101
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Tagworks Pharmaceuticals BV
HER-2 Gene Amplification
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
- Trial name
- NCT01304784
- Testing
- Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Merrimack Pharmaceuticals
Solid Tumors
A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of…
- Trial name
- NCT00404521
- Testing
- PM02734
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- PharmaMar
Claudin18.2 Positive Advanced Solid Tumors
Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T)
A single-center, single-arm, dose-escalation exploratory clinical trial of the safety, efficacy, and pharmacokinetics of XKDCT225 cell injection in Claudin18.2-positive advanced solid tumors
- Trial name
- NCT06782425
- Testing
- XKDCT225
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shenzhen Celconta Life Science Co., Ltd.
Ovarian Cancer, Cervical Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
This is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no…
- Conditions
- Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Breast Cancer
- Trial name
- NCT06846099
- Testing
- RP903
- Where
- 23 sites in China
- Volunteers
- 69 people
- Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.
Advanced Solid Tumor, Recurrent Glioma
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options.
- Trial name
- NCT04089449
- Testing
- PRT811
- Where
- 11 sites in United States
- Volunteers
- 86 people
- Sponsor
- Prelude Therapeutics Incorporated
Solid Tumor, Metastatic Cancer
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all…
- Trial name
- NCT03835949
- Testing
- TJ004309, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Advanced Solid Tumor
Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors
The main objective of this study is to determine the maximum tolerated dose (MTD) of HM781-36B.
- Trial name
- NCT01455571
- Testing
- HM781-36B
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.